Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00849654 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma
A Phase 1 study of B-cell Lymphoma and B-cell Leukemia, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
- 9
- Study locations
NCT00849654 is a Phase 1 study of B-cell Lymphoma and B-cell Leukemia that has completed, run by Pharmacyclics. The registered enrollment target is 66 participants, below the 88-participant average among 38 other B-cell Lymphoma trials with a reported enrollment target (25% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT00849654, a Phase 1 study of B-cell Lymphoma and B-cell Leukemia, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to establish the safety and optimal dose of orally administered PCI-32765 in patients with recurrent B cell lymphoma.
Conditions Studied
Interventions
- DRUG PCI-32765
Study Locations (9)
Washington
- Northwest Cancer Specialists, Vancouver Cancer Center - Vancouver
- Yakima Valley Memorial Hospital/North Star Lodge Cancer Ctr - Yakima
California
- Stanford University School of Medicine - Palo Alto
Illinois
- University of Chicago - Chicago
Maryland
- National Cancer Institute - Bethesda
New York
- New York Prebyterian Hospital Cornell Medical Center - New York
Oregon
- Willamette Valley Cancer Institute/Research Ctr - Eugene
Texas
- University of Texas, MD Anderson - Houston
Vermont
- University of Vermont College of Medicine - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2009-02 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00849654
The ClinicalTrials.gov registry entry for NCT00849654 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 88-participant average among 38 other B-cell Lymphoma trials with a reported enrollment target (25% lower). The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with B-cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which PCI-32765 is the first listed.
NCT00849654 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Washington, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00849654 about?
NCT00849654 is a clinical study titled "Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma". The purpose of this study is to establish the safety and optimal dose of orally administered PCI-32765 in patients with recurrent B cell lymphoma.
What is the current status of trial NCT00849654?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2009-02. Estimated completion is 2012-07.
What conditions does trial NCT00849654 study?
This clinical trial studies the following conditions: B-cell Lymphoma, B-cell Leukemia.
What interventions are being tested in trial NCT00849654?
The interventions under investigation include: PCI-32765 (DRUG).
Who is sponsoring clinical trial NCT00849654?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00849654 being conducted?
This trial has 9 study locations across California, Illinois, Maryland, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
RECRUITING · Phase 1
-
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
RECRUITING · Phase 1
-
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.